AU2003200753B2 - Bioadhesive Progressive Hydration Tablets - Google Patents
Bioadhesive Progressive Hydration Tablets Download PDFInfo
- Publication number
- AU2003200753B2 AU2003200753B2 AU2003200753A AU2003200753A AU2003200753B2 AU 2003200753 B2 AU2003200753 B2 AU 2003200753B2 AU 2003200753 A AU2003200753 A AU 2003200753A AU 2003200753 A AU2003200753 A AU 2003200753A AU 2003200753 B2 AU2003200753 B2 AU 2003200753B2
- Authority
- AU
- Australia
- Prior art keywords
- composition
- active ingredient
- testosterone
- water
- bioadhesive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000227 bioadhesive Substances 0.000 title claims description 55
- 230000036571 hydration Effects 0.000 title claims description 28
- 238000006703 hydration reaction Methods 0.000 title claims description 28
- 230000000750 progressive effect Effects 0.000 title claims description 25
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 160
- 239000004480 active ingredient Substances 0.000 claims description 94
- 229960003604 testosterone Drugs 0.000 claims description 80
- 239000000203 mixture Substances 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 36
- 241000124008 Mammalia Species 0.000 claims description 32
- 229920000642 polymer Polymers 0.000 claims description 30
- 238000013268 sustained release Methods 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000012730 sustained-release form Substances 0.000 claims description 26
- 229920003169 water-soluble polymer Polymers 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 21
- 229960000195 terbutaline Drugs 0.000 claims description 21
- 229920000148 Polycarbophil calcium Polymers 0.000 claims description 20
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 20
- 229950005134 polycarbophil Drugs 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 19
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 claims description 18
- 229960004281 desmopressin Drugs 0.000 claims description 16
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 14
- -1 controlled Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 210000002966 serum Anatomy 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 229960003387 progesterone Drugs 0.000 claims description 10
- 239000000186 progesterone Substances 0.000 claims description 10
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims description 9
- 102000003886 Glycoproteins Human genes 0.000 claims description 8
- 108090000288 Glycoproteins Proteins 0.000 claims description 8
- 238000013270 controlled release Methods 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 229960003473 androstanolone Drugs 0.000 claims description 6
- 230000003388 anti-hormonal effect Effects 0.000 claims description 5
- 239000000935 antidepressant agent Substances 0.000 claims description 5
- 229940005513 antidepressants Drugs 0.000 claims description 5
- 239000000739 antihistaminic agent Substances 0.000 claims description 5
- 229940125388 beta agonist Drugs 0.000 claims description 5
- 239000002876 beta blocker Substances 0.000 claims description 5
- 239000003163 gonadal steroid hormone Substances 0.000 claims description 5
- 150000003180 prostaglandins Chemical class 0.000 claims description 5
- 239000005541 ACE inhibitor Substances 0.000 claims description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 229940125715 antihistaminic agent Drugs 0.000 claims description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 4
- 150000002823 nitrates Chemical class 0.000 claims description 4
- 229940005483 opioid analgesics Drugs 0.000 claims description 4
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 4
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims description 4
- 239000003826 tablet Substances 0.000 description 95
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 28
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 26
- 238000004090 dissolution Methods 0.000 description 24
- 238000009472 formulation Methods 0.000 description 24
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 20
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 20
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 20
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 20
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 18
- 239000008101 lactose Substances 0.000 description 18
- 229920002261 Corn starch Polymers 0.000 description 15
- 239000000454 talc Substances 0.000 description 15
- 229910052623 talc Inorganic materials 0.000 description 15
- 239000008120 corn starch Substances 0.000 description 14
- 239000000377 silicon dioxide Substances 0.000 description 14
- 229940031663 carbomer-974p Drugs 0.000 description 13
- 235000019359 magnesium stearate Nutrition 0.000 description 13
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 12
- 230000015556 catabolic process Effects 0.000 description 11
- 238000006731 degradation reaction Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 239000008187 granular material Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 230000002459 sustained effect Effects 0.000 description 7
- 229920002125 Sokalan® Polymers 0.000 description 6
- 230000002028 premature Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000004622 sleep time Effects 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000006189 buccal tablet Substances 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 230000010224 hepatic metabolism Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 229960005105 terbutaline sulfate Drugs 0.000 description 3
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 3
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 2
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
- 206010058359 Hypogonadism Diseases 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 101710142969 Somatoliberin Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000009165 androgen replacement therapy Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000035587 bioadhesion Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 229960002845 desmopressin acetate Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 102100021752 Corticoliberin Human genes 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- OZYUPQUCAUTOBP-QXAKKESOSA-N Levallorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(CC=C)[C@@H]2CC2=CC=C(O)C=C21 OZYUPQUCAUTOBP-QXAKKESOSA-N 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- 239000000026 Pentaerythritol tetranitrate Substances 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- ODZDZTOROXGJAV-IRWJKHRASA-N [(8r,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 4-butylcyclohexane-1-carboxylate Chemical compound C1CC(CCCC)CCC1C(=O)O[C@@H]1[C@@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4CC[C@H]3[C@@H]2CC1 ODZDZTOROXGJAV-IRWJKHRASA-N 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 description 1
- 229960004620 bitolterol Drugs 0.000 description 1
- 229960003108 brompheniramine maleate Drugs 0.000 description 1
- SRGKFVAASLQVBO-BTJKTKAUSA-N brompheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 SRGKFVAASLQVBO-BTJKTKAUSA-N 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960005450 eritrityl tetranitrate Drugs 0.000 description 1
- SNFOERUNNSHUGP-ZXZARUISSA-N erythrityl tetranitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O SNFOERUNNSHUGP-ZXZARUISSA-N 0.000 description 1
- 229960003745 esmolol Drugs 0.000 description 1
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960002479 isosorbide Drugs 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229960000263 levallorphan Drugs 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- IAVGMIBOMLTFSU-UHFFFAOYSA-L magnesium dioxosilane octadecanoate Chemical compound [Mg+2].O=[Si]=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O IAVGMIBOMLTFSU-UHFFFAOYSA-L 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 229960005297 nalmefene Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960004321 pentaerithrityl tetranitrate Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960001634 ritodrine Drugs 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229940088956 testosterone transdermal system Drugs 0.000 description 1
- 229960000746 testosterone undecanoate Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 239000000003 vaginal tablet Substances 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
S&F Ref: 545288D1
AUSTRALIA
PATENTS ACT 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT
ORIGINAL
Name and Address of Applicant: Actual Inventor(s): Address for Service: Invention Title: Columbia Laboratories (Bermuda) Limited Rosebank Center 14 Bermudiana Road Pembroke HM08 Bermuda William J Bologna Howard L Levine Philippe Cartier Dominique De Ziegler Spruson Ferguson St Martins Tower,Level 31 Market Street Sydney NSW 2000 (CCN 3710000177) Bioadhesive Progressive Hydration Tablets The following statement is a full description of this invention, including the best method of performing it known to me/us:- 5845c BIOADHESIVE PROGRESSIVE HYDRATION TABLETS The present invention relates to bioadhesive, bioerodible compositions for the extended and controlled release of active ingredients treating agents). More particularly, the present invention relates to progressive hydration tablets for adhesion to the wall of a body cavity for the sustained release of active ingredients without premature degradation of the active ingredients caused by metabolism, or by moisture, enzymes or pH effects.
Medications and other pharmaceutical products have traditionally been administered in doses via oral ingestion, nasal sprays or injections. These delivery 0io methods have proven ineffective for patients needing a prolonged and constant supply of an active ingredient delivered to the bloodstream. Particularly difficult are patients needing dosing during sleep time hours. For these patients, intravenous lines, slow-dissolving pills, and suppositories or transdermal patches have been prescribed.
However, the inconvenience and discomfort of IVs, the short life span of many ingested active ingredients from gastrointestinal degradation or first-pass liver metabolism, and the inability of many products to be comfortably delivered transdermally in suitable doses or in controlled concentrations have proven these methods unsatisfactory.
Previous artisans have attempted to meet the needs of the art by developing products for the transmucosal administration of active ingredients. For example, certain active ingredients can be administered quickly into the bloodstream via the walls of a body cavity, such as the buccal or vaginal cavities, without the risk of first pass hepatic degradation. Generally, delivery of active ingredients through mucosal surfaces may be enhanced by the use of bioadhesive formulations. However, one particular area where those in the art have attempted, but heretofore failed, to meet the needs of the art is in developing a bioadhesive tablet useful for sustained release applications without risking degradation of the active ingredient before it is actually released.
"Sustained release" generally refers to continuous or sporadic release of an active ingredient over an extended time after a single administration, whereby the level of active ingredient available to the host patient often is maintained at some constant level over a period of time. As used herein, it is also intended to cover the situation where the release of an active ingredient is controlled over a period of time wherein the level of active ingredient available to the host (bioavailability) may be at a variable but predetermined level at a particular instant in time of treatment.
[I:\DayLib\LIBZZ]545288D1 speci2.doc:mrr The sustained release bioadhesive tablets known in the art can be generally broken down into two categories: tablets consisting of water soluble carbomers, and (2) tablets consisting of insoluble polymers. Both types of tablets have proven unsatisfactory for many applications. For example, numerous artisans have attempted to formulate a suitable sustained release bioadhesive tablet from water soluble carbomers, such as carbomer 934P or CARBOPOLTM 974 resin (commercially available from B.F. Goodrich, Cleveland, Ohio). However, such tablets often are only able to adhere to the wall of a body cavity for short periods of time, six hours or less. Also, these tablets are easily dislodged from the wall of a body cavity and thus place patients using such tablets buccally at risk of asphyxiation. Furthermore, these prior art tablets inherently become hydrated relatively quickly and thus may prematurely expose the reservoir of active ingredient to degradation by moisture or by enzymes from the host environment such as from bacteria in the septic oral or vaginal cavities.
Similarly, tablets comprised of insoluble polymers, such as Polycarbophil, have proven unsuitable for many applications. For example, although Polycarbophil tablets are capable of prolonged attachment to the wall of a body cavity, such tablets do not adhere immediately, making them impractical for certain treatments such a buccal delivery of active ingredients to patients during sleep time hours. Further, such tablets often do not soften sufficiently to provide comfort and imperceptibility, or provide safety from potential aspiration of the tablet.
Furthermore, for example, neither type of prior art tablet is particularly suitable for treating many conditions. As alluded to previously, there are numerous medical conditions in which a sustained and/or controlled release of active ingredient(s) is desired for any of numerous reasons including, for example, to alleviate the impact of first-pass hepatic metabolism of the active ingredient or the risk of premature degradation of the active ingredient by moisture, pH effects, or enzymes, or to attain the comfort and convenience offered by a suitable bioadhesive tablet. Such conditions include, but are not limited to, for example, those needing treatment with an active ingredient that may be, but is not limited to, a glycoprotein, protein, sex hormone, anti-hormone, nitrate, beta-agonist, beta-antagonist, opioid, opioid-antagonist, antidepressant, HMG CoA (3-hydroxy-3methylglutaryl Coenzyme A) reductase inhibitor, antihistamine, ACE (angiotensin converting enzyme) inhibitor, and/or prostaglandin. Heretofore the art has required such patients to undergo the more invasive and less suitable techniques and methods of delivery described above.
I:\DayLib\LIBZZ]545288D1 speci2.doc:mrr To illustrate the need in the art, consider hypogonadal men, for example.
Hypogonadism in man is characterized by a deficiency or absence of endogenous testosterone production. Abnormally low levels of testosterone may place men at risk of "Andropause", wherein men are at greater risk of cardiovascular disease, Alzheimer's disease, and osteoporosis.
Testosterone has traditionally been used to treat hypogonadal men. However, to be most effective, the treatment must be capable of complete physiologic testosterone replacement. Moreover, the treatment must be capable of providing sustained levels of testosterone through the night, preferably sustaining a peak in the middle of the night.
Transdermal testosterone patches typically produce only sub-physiologic levels and thus incomplete relief. Similarly, the prior art buccal tablets heretofore described would be ineffective or impractical for such sustained testosterone delivery.
The hormone testosterone, like many other drugs, including many other proteins and glycoproteins, undergoes high first pass metabolism. Accordingly, as will be appreciated by one of ordinary skill in the art, buccal or vaginal tablets consisting of materials that are incapable of keeping the interior reservoir of the tablet in the dry state for prolonged periods are inherently incapable of preventing dissolution and swallowing or dissolution and rapid absorption of the active ingredient through the mucosa.
Furthermore, as will be appreciated by one of ordinary skill in the art, tablets which are unable to quickly adhere to the target area or are able to become dislodged are impractical for treatments which use night-time delivery, such as testosterone treatment.
Active ingredients such as testosterone may also undergo undesired metabolism. For example, 5ct-reductase converts testosterone to 5ct-dihydrotesterone (DHT). DHT may cause adverse effects such as hair loss and prostate disorders. Similarly, may metabolize other active ingredients such as progesterone.
Various testosterone formulations have been developed to circumvent the problems inherent in rapid clearance of orally and parenterally administered agents. These include transdermal preparations (with or without emollient), pellets for subcutaneous implantation, biodegradable microcapsule formulations for injection, and inclusion complexes that enhance sublingual absorption of the hormone. Of these, the testosterone transdermal system for use on the scrotum and other skin patch products, are probably the most widely tested. Under optimal conditions, they are intended to approximate the physiological pattern of hormone levels throughout the day and provide an alternative to parenteral therapy.
[I:\DayLib\LIBZZ]545288D1 speci2.doc:mrr However, the scrotal preparation causes a disproportionate increase in plasma dihydrotestosterone (DHT) to a level that is 30 to 40% that of testosterone, presumably because of the high level of 5ac-reductase in scrotal skin. Other skin patches likewise produce high levels of DHT. Such increases in serum DHT have also been reported after treatment with the extremely long-acting parenteral testosterone ester testosterone buciclate and with the oral ester testosterone undecanoate. Williams Textbook of Endocrinology, 9 th Ed., W.B. Saunders Company, p. 853. Thus, the present invention advantageously avoids the side effects that may be caused by 5a-reductase's metabolism of active ingredients.
Furthermore, as will be appreciated by one of ordinary skill in the art, the advantages of a sustained release, bioadhesive tablet according to the present invention are not limited to the treatment of hypogonadism in men. For example, patients often require sustained release hormone treatment for various conditions. In addition, other medications, such as steroids for treating such conditions as asthma, involve treatments is where desired peak levels are at night during sleep-time hours. Accordingly, one of ordinary skill in the art will appreciate that there exists a long-felt, yet unresolved, need to develop a bioadhesive, sustained release tablet to overcome the aforementioned needs of the art, including, but not limited to, the delivery of therapeutically effective amounts of an active ingredient which may be metabolized or otherwise degraded by moisture, enzymes, or pH effects, such as glycoproteins, proteins, sex hormones, anti-hormones, nitrates, beta-agonists, beta-antagonists, opioids, opioid-antagonists antidepressants, HMG CoA reductase inhibitors, antihistamines, ACE inhibitors, and/or prostaglandins.
For example, an advantage to administering treating agents such as terbutaline (especially for sleep time administration) through a sustained release bioadhesive tablet according to the instant invention is that such administration provides controlled, extended release to help prevent high peak blood serum levels of the terbutaline. This is particularly useful when the treating agent, such as terbutaline, is associated with adverse side effects at high blood serum levels.
BRIEF DESCRIPTION OF THE DRAWINGS Figure I is a series of photographs depicting the progressive hydration of a bioadhesive tablet according to the invention.
Figure 2 is a flowchart depicting a presently preferred method of making bioadhesive tablets according to the invention.
[1:\DayLib\LIBZZ]545288D 1 speci2.doc:mrr SUMMARY OF THE INVENTION There is described herein a bioadhesive tablet that adheres immediately or almost immediately to the target tissue area of a body cavity and generally stays attached substantially throughout treatment. Also described herein is a bioadhesive tablet that can stay attached and deliver active ingredients in the buccal cavity for as much as eighteen hours or more. There is also described herein a bioadhesive tablet that can stay attached and deliver active ingredients vaginally for as much as 72 hours or more.
Also described herein is a bioadhesive tablet that progressively hydrates, whereby the inner core of the tablet remains protected from moisture and the surrounding environment. In accordance with this aspect there is provided a bioadhesive tablet suitable for sustained release use in mucosal and other body cavities even with active ingredients comprising proteins or glycoproteins or other treating agents that are particularly susceptible to metabolism, or to enzymatic, pH, or moisture-induced degradation.
In a related aspect there is described herein a bioadhesive tablet having both controlled and sustained release properties due to a tablet formulation wherein the active ingredient is only progressively made bioavailable over an extended time period by the progressive hydration of the tablet's dry reservoir of active ingredient.
There is also described herein a bioadhesive tablet that also gelifies and/or swells to help protect a patient using the tablet buccally from asphyxiation, particularly a sleeping patient undergoing treatment.
Also described are methods of making bioadhesive tablets described herein. There is described a method of making bioadhesive tablets wherein an active ingredient resistant to premature metabolism and/or degradation is added in the first and/or second step (manufacture of granulate). There is described a method of making bioadhesive tablets wherein an active ingredient prone to premature metabolism and/or degradation is added in the second step (manufacture of the tableting mixture) after the granulate is dried and sieved. Of course, other concerns or factors may affect the choice of which step or steps are appropriate for'adding a particular active ingredient.
Also described are methods of using bioadhesive tablets as described herein. There is described herein a method of using a bioadhesive tablet to administer to a male patient a sustained release of testosterone. In accordance with a related aspect, there is described a method of using a bioadhesive tablet to administer to a female patient a sustained release of a hormone, such as testosterone.
The inventors of the present invention have discovered, quite unexpectedly, that the above may be achieved by making and using tablets comprising an active ingredient, one or more bioadhesive water soluble polymers carbomer 974P or 934P, or CARBOPOLTM 974P), and one or more bioadhesive, water insoluble water swellable cross-linked polycarboxylic polymers, preferably polycarbophil NOVEON®, available from B.F. Goodrich Specialty Polymers of Cleveland, OH), and preferably hydroxypropylmethyl cellulose (HPMC), lactose, corn starch and other standard tablets ingredients, such as magnesium stearate, talc, and silica.
Bioadhesive, progressive hydration tablets described herein may be used with any to suitable active ingredient and may be used to deliver a therapeutic amount of the active ingredient to a patient at controlled rates for sustained periods of time. The tablets may also be constructed in any suitable shape and any suitable size consistent with the intended therapeutic use of the tablet.
Tablets described herein may comprise any suitable amount of active ingredient.
Suitable amounts of active ingredient according to the invention may be from minuscule amounts to about 50%, or more. As will be appreciated by one of ordinary skill in the art, "minuscule amounts" is intended to cover those amounts of active ingredient that are disproportionately small relative to the tablet, for example, when only a few micrograms of active ingredient are to be delivered via a tablet weighing over a hundred milligrams.
Accordingly, one of ordinary skill in the art will appreciate that any amount of active ingredient, in any ratio, is within the scope of the present invention.
The balance of the tablet described herein may comprise water soluble polymer(s) and water insoluble cross-linked polycarboxylic polymer(s). Also, exemplary tablets preferably have between about 1% and about 75% by weight water soluble polymer (preferably carbomer 974P) and between about 0.5% and about 10% by weight water insoluble, water-swellable cross-linked polycarboxylic polymer (preferably Polycarbophil). Such exemplary tablets also preferably include between about 5% and about 50% cellulose. Presently preferred tablets may have between about 0.5% and about by weight starch. These preferred tablets may also have between about 1% and about 50%, or as much as 95%, by weight lactose.
Furthermore, preferred tablets may comprise from about .01% up to about 2% silica; and/or up to about 5% to 8% by weight talc; and/or up to about 2.5% by weight magnesium stearate.
[I:\DayLib\LIBZZ]545288D 1 speci2.doc:mrr Accordingly, one of ordinary skill in the art will appreciate that the components of the tablets can be varied to suit a particular purpose. For example, the inventors of the present invention have discovered that one way of increasing (decreasing) the time it takes a progressive hydration tablet to hydrate is by increasing (decreasing) the amount of lactose and/or starch and decreasing (increasing) the amount of water soluble polymer.
Alternatively, the density of the tablet may be altered to affect the hydration period.
Active ingredients suitable for use in the present invention include any active ingredient or ingredients requiring sustained or controlled release, any active ingredient or ingredients requiring extended protection from premature degradation by moisture, pH effects, or enzymes, or any active ingredient requiring administration to a patient with protection from first-pass hepatic metabolism. Exemplary active ingredients suitable for use with the present invention include, but are by no means limited to: glycoproteins, such as follicle-stimulating hormone (FSH), luteinizing hormone human chorionic gonadotropin (HCG), thryoid-stimulating hormone (TSH), and the like; proteins, such as GnRH (agonist and antagonist), oxytocin analogs, somatostatin analogs, tissue plaminogen activator (TPA), growth hormone releasing hormone (GHRH), corticotropinreleasing hormone analogs (CRH analogs), and the like; sex hormones, such as estradiol, testosterone, progesterone, and the like; anti-hormones, such as tamoxifen, mifepristone, and the like; nitrates, such as nitroglycerin, isosorbide, erythrityl tetranitrate, pentaerythritol tetranitrate, and the like; beta-agonists, such as terbutaline, albuterol, pirbuterol, bitolterol, ritodrine, and the like; beta-antagonists, such as propranolol, metoprolol, nadolol, atenolol, timolol, esmolol, pindolol, acebutolol, labetalol, and the like; opioids, such as morphine, hydromorphone, oxymorphone, codeine, hydrocodone, oxycodone, leverophanol, levallorphan, buprenorphine, fentanyl, nalbuphine, butorphanol, pentazocine, and the like; opioids-antagonists, such as naloxone, nalmefene, and the like; (10) antidepressants, such as amitriptyline, amoxapine, desipramine, doxepin, imipramine, maprotilen, nortriptyline, protripyline, trimipramine, fluoxetine, trazodone, and the like; (11) HMG CoA reductase inhibitors, such as lovastatin, mevastatin, simvastatin, pravastatin, atorvastatin, and the like; (12) antihistamines, such as loratadine, chlorpheniramine maleate, brompheniramine maleate, diphenhydramine, dimenhydrinate, carbinoxamine, promethazine, tripelannamine, and the like; (13) ACE inhibitors, such as captopril, enalapril, lisinopril, and the like; and, (14) prostaglandins, such as misoprostol and the like. Accordingly, one of ordinary skill in the [[:\DayLib\LIBZZ]545288D 1speci2.doc:mrr art will appreciate that tablets according to the invention may be used with a wide variety of active ingredients to treat a wide variety of conditions.
There is also described herein a pharmaceutical composition comprising an effective amount of active ingredient, a water insoluble, water-swellable cross-linked polycarboxylic polymer, and a water soluble polymer, wherein said composition is formulated to deliver said active ingredient to the bloodstream of a mammal through a mucosal surface of the mammal.
Also described herein is a method of delivering to a mammal an active ingredient that is metabolized by 5a-reductase, comprising administering said active ingredient via a o0 progressive hydration bioadhesive composition through a mucosal surface of the mammal.
In addition, there is also described herein a composition for delivering to the bloodstream of a mammal an active ingredient that is metabolized by comprising a water insoluble cross-linked polycarboxylic polymer, and a water soluble polymer, wherein said composition is formulated to deliver said active ingredient through a mucosal surface of the mammal.
In addition, there is also described herein a bioadhesive progressive hydration pharmaceutical composition comprising: an effective amount of a treating agent, a water insoluble, water-swellable cross-linked polycarboxylic polymer, and a water soluble polymer, wherein said composition is formulated to deliver said treating agent to the bloodstream of a mammal through a mucosal surface of the mammal.
In addition, there is described herein a bioadhesive progressive hydration pharmaceutical composition comprising an effective amount of terbutaline, progesterone, testosterone, or desmopressin, a water insoluble, water-swellable cross-linked polycarboxylic polymer, and a water soluble polymer, wherein said composition is formulated to deliver said terbutaline, progesterone, testosterone, or desmopressin, to the bloodstream of a mammal through a mucosal surface of the mammal.
In addition, there is described herein a method of delivering to a mammal an effective amount of a treating agent, including without limitation, testosterone, terbutaline, progesterone, or desmopressin via a progressive hydration bioadhesive pharmaceutical composition through a mucosal surface of the mammal, comprising said treating agent, a water insoluble, water-swellable cross-linked polycarboxylic polymer, and a water soluble polymer.
[I:\DayLib\LIBZZ]545288D I speci2.doc:mrr Preferably, the compositions described herein are formulated to deliver said active ingredient via the mammal's vaginal, buccal, nasal or rectal cavity.
According to a first embodiment of the invention there is provided a bioadhesive controlled, sustained release progressive hydration pharmaceutical composition comprising: an effective amount of an active ingredient, a water insoluble, water-swellable cross-linked polycarboxylic polymer, and a water soluble polymer, wherein said composition is formulated to deliver the active ingredient to the bloodstream of a mammal through a mucosal surface of the mammal.
According to a second embodiment of the invention there is provided a method for delivering to a mammal an active ingredient, comprising administering the active ingredient via a controlled, sustained release progressive hydration bioadhesive composition through a mucosal surface of the mammal the bioadhesive composition comprising a water-insoluble, water-swellable, cross-linked polycarboxylic polymer, a water soluble polymer, and the active ingredient.
According to a third embodiment of the invention there is provided the use of a water insoluble, water-swellable cross-linked polycarboxylic polymer, a water soluble polymer, and an active ingredient, in the manufacture of a bioadhesive, controlled, sustained release progressive hydration medicament for transmucosal administration in a mammal.
According to a fourth embodiment of the invention there is provided a bioadhesive, controlled, sustained release progressive hydration pharmaceutical composition comprising a water insoluble, water-swellable, cross-linked, polycarboxylic polymer, a water soluble polymer, and an active ingredient, for use in a method of therapeutic treatment of the human or animal body comprising transmucosal administration of the active ingredient.
According to a fifth embodiment of the invention there is provided a method of delivering to a mammal an effective amount of a treating agent comprising one or more of progesterone, terbutaline, desmopressin, or testosterone via a controlled and sustained release, progressive hydration bioadhesive pharmaceutical composition through a mucosal surface of the mammal, said method comprising administering an effective amount of a composition comprising the treating agent, a water insoluble, water swellable, cross-linked polycarboxylic polymer, and a water soluble polymer to the mucosal surface of said mammal.
According to a sixth aspect of the invention there is provided a bioadhesive, controlled, sustained release progressive hydration pharmaceutical composition comprising a water insoluble, water-swellable, cross-linked, polycarboxylic polymer, a water soluble polymer, and an active ingredient, when used in a method of therapeutic treatment of the human or animal body comprising transmucosal administration of the active ingredient.
The aforementioned and other aspects described herein will become more clear by reference to the Figures and descriptions of preferred embodiments.
A preferred embodiment of the invention is depicted in Figure 1. As shown in the first-frame of Figure 1, before the tablet is administered all of the active is in the dry state and thus, not subject to the deleterious action of moisture, pH effects, enzymes or other chemicals. It is also not available for absorption (bioavailable). As shown in frames 2-6 of Figure 1, over time the residual portion of the active remains in the dry state which both protects it from water and the immediate environment as well as allowing it to serve as a reservoir for the sustained and controlled release of the active. Such a delivery system is well suited for the delivery of proteins, glycoproteins, and other drugs which must be protected from metabolism or during prolonged administration from enzymatic, pH, or moisture-induced degradation.
In a preferred embodiment, when used buccally, progressive hydration of the bioadhesive tablet protects the patient, should the tablet become dislodged, by gelifying and becoming heavier and thus less likely to float in the airway, risking aspiration. This 0to makes this embodiment particularly well suited for agents that should reach their peak levels in the middle of the night, hormones like testosterone or steroids to treat asthma. According to the invention, the hydration of the tablet can preferably take hours 12 to 24 hours) when formulated for buccal tablets or even days when formulated for vaginal use. As will be appreciated by one of ordinary skill in the art, prior art bioadhesive tablets do not protect the active ingredient from moisture, pH, or from enzymes produced by bacteria in the septic oral and vaginal orifices.
Furthermore, as will be appreciated by one of ordinary skill in the art following the teaching of the present application, the tablet can be sized, shaped and dosed to meet the needs of the particular treatment being undertaken. For example, the buccal bioadhesive tablet depicted in Figure 1 was constructed to be only 9mm in diameter for the comfort of the patient, but made capable of delivering 7mg of testosterone per day, full physiologic level. By contrast, prior art transdermal patches were only capable of delivering 5mg per day, in other words a sub-physiologic level.
A presently preferred method of manufacturing bioadhesive tablets is diagramed in 2s Figure 2. The presently preferred method involves three steps as described below: 1. First step: manufacture of the granulate.
Hydroxypropylmethyl cellulose 15000(=HPMC 15000) is mixed with corn starch and lactose and in case of an active ingredient not sensitive to moisture the active is added. The mixture is wet with an aqueous solution of hydroxypropylmethyl cellulose (=HPMC 5) and knead/granulated.
The granulate is dried in an oven under warm air (50 0 C) until moisture content is less than The dried granulate is broken with a stainless steel sieve oscillating granulator mesh size 1000 gm, I i:\DayLib\LIBZZ]545288D I speci2.doc:mrr 2. Second step: the tableting mixture.
Talc, silicon dioxide magnesium stearate, and in a case of an active ingredient sensitive to moisture, the active ingredient is added. All is sieved through a sieving machine having aperture size 500 am and then transferred into a free-fall mixer.
Addition of the granulate of step 1, followed by polycarbophil, carbomer and lactose. The whole is mixed until homogenous.
3. Third step: tableting.
The tableting mixture is compressed into tablets by means of a rotative tableting machine equipped with punches 9mm flat on the upper side and curved (r=9mm) on the 0to lower side both with beveled edge. The tablets are dedusted and packed.
As depicted in Figure 2, an active ingredient that is not sensitive to moisture is preferably added during the manufacture of the granulate. However, alternatively, the active ingredient can be added during the second step after the granulate is dried and sieved. Also, as will be appreciated by one of ordinary skill in the art, this second method is particularly preferred when the active ingredient is sensitive to moisture.
In a presently preferred manufacturing process, the active ingredient is preferably protected from moisture. A wet granulation is made of lactose, corn starch and HPMC.
Testosterone, polycarbophil, carbomer 974P, talc and magnesium stearate are added dry for the final compression.
Furthermore, as will be appreciated by one of ordinary skill in the art following the teaching of the present application, the materials of construction can be varied to optimize the desired characteristics of the tablet. For example, the present inventors have discovered that by progressively increasing the amount of lactose and corn starch and progressively decreasing the amount of carbomer 974P, the amount of time it takes a tablet to hydrate is progressively increased. Accordingly, as will be appreciated by one of ordinary skill in the art, tablets suited for specific treatments specific active, specific dose, specific delivery time) can be manufactured.
These and other aspects of the invention may be more clearly shown by way of example.
[:\DayLib\LIBZZ]545288D I speci2.doc:mrr EXAMPLE 1: TESTOSTERONE TABLET The following is an example of a formulation (Formulation 8, batch #00029906) designed for complete physiologic replacement of testosterone in men: INGREDIENT AMOUNT %w/w Testosterone 30.000 mg 24.0% HPMC 26.250 mg 21.0% Corn Starch 22.500 mg 18.0% Monohydrated Lactose 30.125 mg 24.1% 0o Silica 1.250 mg Polycarbophil (Noveon) 3.125 mg Carbomer 974P 9.375 mg Talc 1.500 mg 1.2% Magnesium stearate 0.875 mg 0.7% Formulations like the one above produced sustained release in in-vitro dissolution tests. When used in female subjects formulas like this one also produce a sustained and controlled release of testosterone for 12 hours or more.
Testosterone formulations have resulted in mean blood serum concentration ratios of testosterone to 5a-dihydrotestosterone (DHT) of 9.25 and 9.29 to 1, to as high as about 12 to 1, in the bloodstream of said mammal. It is contemplated that this mean serum concentration ratio preferably is about 9 to 1 to about 12 to 1.
The individual ingredients are well known and readily available from suppliers known in the industry.
HPMC, or hydroxypropylmethylcellulose, is a swelling, dispersing agent.
Alternates, which are well-known in the industry, include other water-swellable forms of cellulose and polymers.
Corn (maize) starch is a filler and binder. Alternates are well-known in the industry.
Lactose is a filler. Alternatives are well-known in the industry.
Silica, or silicon dioxide (silicium dioxyde), acts as a suspending and thickening agent. Alternatives are well-known in the industry.
Talc and magnesium stearate are lubricant powders commonly used in the manufacture of compressed tablets. Alternatives are well-known in the industry.
[I:\DayLib\LIBZZ]545288 D speci2.doc:mrr Carbomer 934P or 974P (or CARBOPOL T M 974P) is the water soluble polymer.
This polymer provides the initial bioadhesion. Alternatives are well-known in the industry, and include, for example, other water-soluble polymers.
Polycarbophil is the water insoluble polymer, and provides the extended bioadhesion. Alternatives would include, for example, other water-insoluble, waterswellable bioadhesive polymers.
Table 1 depicts nine different formulations of bioadhesive tablets according to the invention. The active ingredient, testosterone, was held constant at 30.0 mg (24% by weight) so the effect of varying the proportions of the inactive ingredients could be io studied.
The testosterone dissolution rates of selected formulations were then studied. Table 2 depicts the testosterone dissolution rate of six tablets selected from Formula 1, batch #0069904. Table 3 depicts the testosterone dissolution rate of six tablets selected from Formula 3, batch #0049904. Table 4 depicts the testosterone dissolution rate of six tablets selected from Formula 5, batch #0029904. Table 5 depicts the testosterone dissolution rate of Formula 6, batch #0019904.
The dissolution rate data was then graphed to illustrate the percent of testosterone released per hour. Chart 1 depicts the testosterone release rate for Formula I (see Table Chart 2 depicts the testosterone release rate for Formula 3 (see Table Chart 3 depicts the testosterone release rate for Formula 5 (see Table Chart 4 depicts the testosterone release rate for Formula 6 (see Table [I:DayLib\LIBZZ545288D I speci2.doc:mrr Testosterone KT Form. I Foff 3 oPomS Fa Poim 5 Fom 6 Fam'7 PointS Form 9 B 069904 0059904 0049904 D0039904 0029904 009904 00019906 00029906 00039906 Mg %y tog %by Mq fly 17g %by IT fly %b fly ig %ly Mo %y tog fby.
Weight Weight Weight Wdend Weight Wdg Weight Weight Weights Testotene 30.000 24.00 30.000 24.00 30.000 24.00 30.000 24.00 30.000 24.00 30.0-00 24.00 30.000 24,00 30.000 -24.00 30.000 24.00 31.250 25.00 30.000 24.00 28.750 23.00 27.500 22.00 2615 2100D 26501 21.00 262502.00 26.250 2100 26-250 21.00 35000 Cornstrch 2.50 2.00 O 6.00 12500 10.I0 17.5W 14.00 22 .1 38.00 2250 38.00 22.500 18.00 22.500 .1.00 22.500 18.00 Monohydrted 11,375 9.10 13.175 11.10 1675 13.10 18.87 15.30 21.375 17.10 2400 19.60 27.62 22.10 30-125 24.10 33.250 26.60 Silica 3.250 1.00 3.250 1.0 1.250. 1.00 1250 3.00 1.250 .00 350 140 1250 1.00 1,250 1 00 1-250 1.00 Polycbophil 3.125 2.50 3.125 2.50 3.125 2.50 3.125 2.50 3.125 2.50 3.125 2.50 3.125 2.50 3.125 2.50 3.125 2.50 acid (Noveco Carbaonr 43.750 35.00 37.500 3000 31.250 25.00 25.00 200 38-50 15.00 15.625 32.50 1250 30.00 9-375 7.50 6250 5.00 974P Talc 0.875 0.70 0.175 0.70 0.975 0.70 61275 070 0175 0.70 0.875 0.70 1 O 0.70 I'm0 3.20 1.500 1.20 Mapaiwn 015 0170 0,875 0.70 01.75 0.10 0.875 0.70 O175 0.70 0.875 0.70 015 -0.70 01975 (.701 0.875 0.70 Totl WIeig 125300 1000 3100 100 125.00 1010 125100 12500 100 2 00 121000 1 00 125.00 10010 12 0 1001 150 100.00 *hryd,,V,,pyI,,ehyI "11,16s TABLE 1 1. I ll TESTOSTERONE DISSOLUTION RATE PERCENT DISSOLUTION BATCH: 0069904 (Formula 1) DISSOLUTION APPARATUS: ROTATING PADDLE 60 RPM PLATINUM WIRE SPIRAL SAMPLE WITHDRHDRAW WITHDRAW WIRAW WITHDRAW WITHDRAW WITHDRAW WITHDRAW WITHDRAW (HOUR) (HOUR) (HOUR) (HOUR) (HOUR) (HOUR) (HOUR) 0 1 2 4 6 8 24 1 0.0 0.7 1.9 7.6 10.6 16.0 83.6 2 0.0 0.6 1.7 6.7 11.7 18.0 88.5 3 0.0 0.7 2.0 6.9 11.7 17.9 84.9 4 0.0 0.6 1.7 7.0 11.2 17.1 88.3 0.0 0.7 1.9 6.8 10.9 17.0 87.4 6 0.0 0.7 2.1 6.6 12.4 18.3 86.6 AVERAGE 0.0 0.7 1.9 6.9 11.4 17.4 86.6
VALUE__
TABLE 2 TESTOSTERONE DISSOLUTION RATE PERCENT DISSOLUTION BATCH: 0049904 (Formula 3) DISSOLUTION APPARATUS: ROTATING PADDLE 60 RPM PLATINUM WIRE SPIRAL SAMPLE WITHDRAW WITHDRAW WITHDRAW WITHDRAW WITHDRAW WITHDRAW WITHDRAW (HOUR) (HOUR) (HOUR) (HOUR) (HOUR) (HOUR) (HOUR) 1 2 4 6 8 24 1 0.0 0.9 3.1 5.6 10.6 16.5 83.6 2 0.0 1.1 3.1 5.6 10.5 16.9 82.2 3 0.0 1.2 3.4 6.3 11.8 18.0 83.4 4 0.0 0.9 2.9 5.4 10.8 16.7 82.7 0.0 1.1 4.9 5.7 10.6 16.7 83.0 6 0.0 1.0 2.9 5.6 11.0 16.8 85.6 AVERAGE 0.0 1.0 3.4 5.7 10.9 16.9 83.4 TABLE 3 TESTOSTERONE DISSOLUTION RATE PERCENT DISSOLUTION BATCH: 0029904 (Formula DISSOLUTION APPARATUS: ROTATING PADDLE 60 RPM PLATINUM WIRE SPIRAL SAMPLE WITHDRAW WITHDRAW WITHDRAW WITHDRAW WITHDRAW WITHDRAW WITHDRAW (HOUR) (HOUR) (HOUR) (HOUR) (HOUR) (HOUR) (HOUR) _0 1 2 4 6 8 24 1 0.0 0.9 2.2 5.9 10.8 16.3 80.3 2 0.0 0.9 2.5 6.7 11.8 17.8 87.5 3 0.0 0.9 2.4 6.9 12.3 17.7 75.2 4 0.0 0.9 2.3 6.8 12.4 18.6 82.4 0.0 0.9 2.5 6.9 12.9 19.5 83.2 6 0.0 0.9 2.2 6.6 12.2 18.8 86.6 AVERAGE 0.0 0.9 2.4 6.6 12.1 18.1 82.5
VALUE
TABLE 4 TESTOSTERONE DISSOLUTION RATE PERCENT DISSOLUTION BATCH: 0019904 (Formula 6) DISSOLUTION APPARATUS: ROTATING PADDLE 60 RPM PLATINUM WIRE SPIRAL SAMPLE WITHDRAW WITHDRAW WITHDRAW WITHDRAW WITHDRAW WITHDRAW WITHDRAW (HOUR) (HOUR) (HOUR) (HOUR) (HOUR) (HOUR) (HOUR) 0 1 2 4 6 8 24 1 0.0 1.2 2.1 5.9 11.1 16.1 71.7 2 0.0 0.8 2.0 5.0 9.7 14.1 70.1 3 0.0 0.9 2.3 6.4 11.3 15.8 74.6 4 0.0 0.9 2.0 5.5 10.4 15.0 68.6 0.0 0.8 1.8 4.9 9.9 14.6 76.6 6 0.0 0.9 1.8 4.9 9.1 13.1 70.3 AVERAGE 0.0 0.9 2.0 5.4 10.3 14.8 72.0
VALUE_
TABLE CHART 1 FORMULA 1 OF TESTOSTERONE RELEASE (DISSOLUTION/ROTATING PADDLE 60 RPM PLATINUM SPIRAL) SINGLE VALUE BATCH 0069904 90.0 80.0- 80.0 70.0-- 60.0
%OF
TESTOSTERONE 50.0
RELEASED
0 2 4 6 8 10 12 14 16 18 20 22 24 26 TIME (HOUR) 1 3 6 CHART 2 OF TESTOSTERONE RELEASE (DISSOLUTION/ROTATING PADDLE 60 RPM PLATINUM SPIRAL) SINGLE VALUE BATCH 0049904 100.
OF
TESTOSTERONE
RELEASED 40.
0 0 0 0 f 0 I- I 1 I- I I I I 0 ii I I I I I 1 I r
,I
1nl I II I -J
UJI
.a t0 I -I I I I I m I 1
UI
0.0 h j -r i i i _I 0 2 4 6 8 10 12 14 16 18 20 22 24 TIME (HOUR) 1--1 2 -4-5 6 CHART 3 OF TESTOSTERONE RELEASE (DISSOLUTION/ROTATING PADDLE 60 RPM PLATINUM SPIRAL) SINGLE VALUE BATCH 0029904 100.0- 90.0 80.0
%OF
TESTOSTERONE
RELEASED
70.0 60.0 50.0 40.0 30.0 20.0 10.0 0.0 8 10 12 14 16 18 21 TIME (HOUR) -1 -6l CHART 4 OF TESTOSTERONE RELEASE (DISSOLUTION/ROTATING PADDLE 60 RPM PLATINUM SPIRAL) SINGLE VALUE BATCH 0019904
%OF
TESTOSTERONE
RELEASED
100.0 90.0 80.0 70.0 60.0 50.0 40.0 30.0 20.0 10.0 0.0 8 10 12 14 16 18 2 TIME (HOUR) I--1 2 4--5 As shown in the charts and tables, by decreasing the amount of lactose and corn starch and increasing the amount of water-soluble polymer, the time it takes for the tablet to hydrate is progressively decreased. Formulation 1 (0069904) and others like it with high levels of carbomer 974P and low levels of lactose and corn starch are probably best suited to buccal administration where 12 hours of delivery is usually sufficient. In the first example given above Formulation 8 (0029906), where the levels of lactose and corn starch are high and carbomer 974P is low, the formula is probably better suited for vaginal administration where release is often required over a period of days.
EXAMPLE 2: TESTOSTERONE TABLET (30 mg) The following is an example of a formulation designed therapy: for testosterone replacement R ,REnTFMNT A MT INT/tthlpt o.w/w INQRE JENT A C T W hn], i t 0/-UU/ Testosterone
HPMC
Corn Starch Lactose Silica Polycarbophil (Noveon) Carbomer 974P Talc Magnesium stearate 30.000 mg 26.250 mg 22.500 mg 45.125 mg 1.250 mg 3.125 mg 9.375 mg 1.500 mg 0.875 mg 21.4% 18.8% 16.1% 32.2% 0.9% 2.2% 6.7% 1.1% 0.6% EXAMPLE 3: TESTOSTERONE TABLET (6 mg) The following is an example of a formulation designed for testosterone replacement therapy:
INGREDIENT
Testosterone
HPMC
Corn Starch Lactose Silica AMOUNT/tablet 6.000 mg 5.250 mg 4.500 mg 78.970 mg 0.700 mg %w/w 5.3% 79.0% 0.7% [I:\DayLib\L1BZZ]545288D1 speci2.doc:mrr Polycarbophil (Noveon) 2.230 mg 2.2% Carbomer 974P 1.000 mg Talc 0.850 mg 0.9% Magnesium stearate 0.500 mg EXAMPLE 4: TESTOSTERONE TABLET (3 mg) The following is an example of a formulation designed for testosterone replacement therapy: INGREDIENT AMOUNT/tablet %w/w Testosterone 3.000 mg HPMC 2.625 mg 2.6% Corn Starch 2.250 mg 2.3% Lactose 86.845 mg 86.8% Silica 0.700 mg 0.7% Polycarbophil (Noveon) 2.230 mg 2.2% Carbomer 974P 1.000 mg Talc 0.850 mg 0.9% Magnesium stearate 0.500 mg Testosterone dosage levels as low as 3 mg have been tested on female patients. The 3 mg dosage produced serum levels of about 1-1.5 ng/ml. This is about 3-6 times greater than would typically be desired to supplement women with testosterone. Thus, as the serum levels achieved from testosterone dosing are linear with respect to the dosage in the formulation, doses of around 0.5-1 mg should be sufficient to replace testosterone in women.
In men, it would be desirable to replace testosterone using a formulation that lasts about 16-18 hours. Dosage levels of 30 mg supply physiologic concentrations of testosterone when administered twice daily, once every 12 hours. Thus, a 16-18 hour formulation would require about 45 mg to supply physiologic testosterone replacement.
EXAMPLE 5: TERBUTALINE TABLET (4 MG) The following is an example of a terbutaline formulation designed to provide certain therapeutic benefits of terbutaline administration: [1:\DayLib\LIB2Z]545288D speci2.doc:mrr
INGREDIENT
Terbutaline sulfate
HPMC
Corn Starch Lactose Silica Polycarbophil (Noveon) Carbomer 974P to Talc Magnesium stearate AMOUNT/tablet 4.000 mg 18.760 mg 16.070 mg 39.640 mg 0.900 mg 2.235 mg 6.700 mg 1.070 mg 0.625 mg %w/w 4.4% 20.8% 17.9% 44.0% 7.4% 1.2% 0.7% EXAMPLE 6: TERBUTALINE TABLET [2 MG] The following is an example of a terbutaline formulation designed to provide certain therapeutic benefits ofterbutaline administration: TNGR 'TITF.NT AMlTT INT/tnhlpt %oW/W rNGRE IE T AMOIWTVI t qhI,,t I/ W/W Terbutaline Sulfate
HPMC
Corn Starch Lactose Silica Polycarbophil (Noveon) Carbomer 974P Talc Magnesium stearate 2.000 mg 18.760 mg 16.070 mg 41.640 mg 0.900 mg 2.235 mg 6.700 mg 1.070 mg 0.625 mg 2.2% 20.8% 17.9% 46.3% 7.4% 1.2% 0.7% EXAMPLE 7 TERBUTALINE TABLET [1MG] The following is an example of a terbutaline formulation designed to provide certain therapeutic benefits ofterbutaline administration: INGREDTENT AMOTINT/tshlet %w/w AMOUT/tblet %w/ Terbutaline Sulfate
HPMC
1.000 mg 18.760 mg 1.1% 20.8% [I:\DayLib\LIBZZ]545288D Ispeci2.doc:mrr Corn Starch 16.070 mg 17.9% Lactose 42640 mg 47.4% Silica 0.900 mg Polycarbophil (Noveon) 2.235 mg Carbomer 974P 6.700 mg 7.4% Talc 1.070 mg 1.2% Magnesium stearate 0.625 mg 0.7% EXAMPLE 8 DESMOPRESSIN TABLET [0.1MG] The following is an example of a desmopressin formulation designed to provide certain therapeutic benefits of desmopressin administration: INGREDIENT AMOUNT/tablet Desmopressin Acetate 0.105 mg Magnesium Stearate 1.000 mg Silicon Dioxide 1.000 mg Talc 1.000 mg Hydroxypropylmethylcellulose 5cps 1.500 mg Polycarbophil (Noveon) 2.235 mg Carbopol 971P 6.700 mg Hydroxypropylmethylcellulose 100,000cps 20.000 mg Lactose, anhydrous 32.460 mg Lactose, monohydrate 34.000 mg EXAMPLE 9 DESMOPRESSIN TABLET [0.2MG] The following is an example of a desmopressin formulation designed to provide certain therapeutic benefits ofdesmopressin administration: INGREDIENT AMOUNT/tablet Desmopressin Acetate 0.210 mg Magnesium Stearate 1.000 mg Silicon Dioxide 1.000 mg Talc 1.000 mg Hydroxypropylmethylcellulose 5cps 1.500 mg :\DayLib\LIBZZ]545288D1 speci2.doc:mrr Polycarbophil (Noveon) 2.235 mg Carbopol 971P 6.700 mg Hydroxypropylmethylcellulose 1 00,000cps 20.000 mg Lactose, anhydrous 32.460 mg Lactose, monohydrate 33.895 mg Data on desmopressin suggests that the 0.1 mg and 0.2 mg dosages provide serum concentrations that are linear with respect to dosages administered in a formulation.
Some formulations have shown mean serum concentrations of about 60 pg/ml, ranging up lo to about 100 pg/ml. This concentration is extremely high and needs to be decreased about 4-fold. In addition, the use of this product in children will necessitate the dosage being reduced even further to about 0.025 mg.
As will be appreciated by one of ordinary skill in the art, the examples and preferred embodiments are not intended to be limiting, and the invention applies to tablets Is comprised of any active ingredient and any combination of tablet materials. Furthermore, as will be appreciated by one of ordinary skill in the art, the invention is intended to cover the methods of manufacturing and therapeutic uses of the aforementioned tablets.
The invention being thus described, it will be apparent to those skilled in the art that the same may be varied in many ways without departing from the spirit and scope of the invention. Such variations are included within the scope of the appended claims.
All publications and patents or applications mentioned in this specification are herein incorporated by reference to the same extent as if each was specifically and individually indicated to be incorporated by reference.
[I:\DayLib\LIBZZ]545288D 1 speci2.doc:mrr
Claims (29)
1. A bioadhesive controlled, sustained release progressive hydration pharmaceutical composition comprising: an effective amount of an active ingredient, a water insoluble, water-swellable cross-linked polycarboxylic polymer, and a water soluble polymer, wherein said composition is formulated to deliver the active ingredient to the bloodstream of a mammal through a mucosal surface of the mammal.
2. The composition of claim 1, wherein the active ingredient comprises one or more of testosterone, progesterone, terbutaline, or desmopressin.
3. The composition of claim 1, wherein the active ingredient comprises testosterone and is present in an amount of about 0.5 mg to 45 mg per unit dosage of the composition.
4. The composition of claim 3, wherein the composition is formulated so as to provide a blood serum concentration ratio of testosterone to (DHT) of about 9 to 1 to about 12 to 1 in the bloodstream of the mammal in use.
The composition of any one of claims 1 to 4, formulated to deliver the active ingredient via the buccal, vaginal, nasal, or rectal cavity.
6. The composition of any one of claims 1 to 5, wherein the water insoluble, water-swellable cross-linked polycarboxylic polymer is polycarbophil.
7. A method for delivering to a mammal an active ingredient, comprising administering the active ingredient via a controlled, sustained release progressive hydration bioadhesive composition through a mucosal surface of the mammal the bioadhesive composition comprising a water-insoluble, water-swellable, cross-linked polycarboxylic polymer, a water soluble polymer, and the active ingredient.
8. The method of claim 7, wherein the active ingredient comprises one or more of testosterone, terbutaline, desmopressin, or progesterone.
9. The method of claim 8, wherein the active ingredient comprises testosterone, and the method provides a blood serum concentration ratio of testosterone to dihydrotestosterone (DHT) of about 9 to 1 to about 12 to 1 in the bloodstream of the mammal.
The method of claim 8, wherein the active ingredient comprises testosterone and is present in an amount of about 0.5 mg to 45 mg per unit dosage of the composition.
11. The method of any one of claims 7 to 10, wherein the composition is formulated to deliver the active ingredient via the buccal, vaginal, nasal, or rectal cavity.
12. The method of any one of claims 8 to 11, wherein the water insoluble, water- swellable cross-linked polycarboxylic polymer is polycarbophil.
13. Use of a water insoluble, water-swellable cross-linked polycarboxylic polymer, a water soluble polymer, and an active ingredient, in the manufacture of a bioadhesive, controlled, sustained release progressive hydration medicament for transmucosal administration in a mammal.
14. The use of claim 13, wherein the active ingredient comprises one or more of testosterone, terbutaline, desmopressin, or progesterone.
The use of claim 14, wherein the active ingredient comprises testosterone, and the medicament provides a blood serum concentration ratio of testosterone to dihydrotestosterone (DHT) of about 9 to 1 to about 12 to 1.
16. A bioadhesive, controlled, sustained release progressive hydration pharmaceutical composition comprising a water insoluble, water-swellable, cross-linked, polycarboxylic polymer, a water soluble polymer, and an active ingredient, for use in a method of therapeutic treatment of the human or animal body comprising transmucosal administration of the active ingredient.
17. The composition of claim 16, wherein the treating agent comprises one or more of glycoproteins, proteins, sex hormones, anti-hormones, nitrates, beta-agonists, beta-antagonists, opioids, opioids-antagonists, antidepressants, HMG CoA reductase inhibitors, antihistamines, ACE inhibitors, or prostaglandins.
18. The composition of claim 17, wherein the composition is formulated as a tablet for delivery of the treating agent via the buccal or vaginal cavity.
19. The composition of claim 17, wherein the treating agent comprises terbutaline which is present in an amount of about 1 mg to 4 mg per unit dosage of the composition.
The composition of claim 17, wherein the treating agent comprises desmopressin which is present in an amount of about 0.025 mg to 0.2 mg per unit dosage of the composition.
21. The composition of any one of claims 17 to 20, wherein the water insoluble, water-swellable cross-linked polycarboxylic polymer is polycarbophil.
22. A method of delivering to a mammal an effective amount of a treating agent comprising one or more of progesterone, terbutaline, desmopressin, or testosterone via a controlled and sustained release, progressive hydration bioadhesive pharmaceutical composition through a mucosal surface of the mammal, said method comprising administering an effective amount of a composition comprising the treating agent, a water insoluble, water swellable, cross-linked polycarboxylic polymer, and a water soluble polymer to the mucosal surface of said mammal.
23. The method of claim 22, wherein the water insoluble, water-swellable cross- linked polycarboxylic polymer is polycarbophil.
24. The method of claim 22, wherein the treating agent comprises one or more of glycoproteins, proteins, sex hormones, anti-hormones, nitrates, beta-agonists, beta- antagonists, opioids, opioids-antagonists, antidepressants, HMG CoA reductase inhibitors, antihistamines, ACE inhibitors, or prostaglandins.
The method of claim 22, wherein the treating agent comprises testosterone and is present in an amount of about 0.5 mg to 45 mg per unit dosage of the composition.
26. The method of claim 22, wherein the treating agent comprises desmopressin and is present in an amount of about 0.025 mg to 0.2 mg per unit dosage of the composition.
27. The method of claim 22, wherein the treating agent comprises terbutaline and is present in an amount of about 1 mg to 4 mg per unit dosage of the composition.
28. A bioadhesive controlled, sustained release progessive hydration pharmaceutical composition according to claim 1, substantially as hereinbefore described with reference to any one of the examples.
29. The method according to claim 7 or 22, wherein said composition is a composition according to claim 28. A bioadhesive, controlled, sustained release progressive hydration pharmaceutical composition comprising a water insoluble, water-swellable, cross-linked, polycarboxylic polymer, a water soluble polymer, and an active ingredient, when used in a method of therapeutic treatment of the human or animal body comprising transmucosal administration of the active ingredient. Dated 22 April, 2005 Columbia Laboratories (Bermuda) Limited Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003200753A AU2003200753B2 (en) | 1998-08-25 | 2003-02-28 | Bioadhesive Progressive Hydration Tablets |
| AU2005203703A AU2005203703B2 (en) | 1998-08-25 | 2005-08-12 | Bioadhesive progressive hydration tablets |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60/097843 | 1998-08-25 | ||
| US09/379310 | 1999-08-23 | ||
| AU55826/99A AU754880B2 (en) | 1998-08-25 | 1999-08-24 | Extended release buccal bioadhesive tablet |
| AU2003200753A AU2003200753B2 (en) | 1998-08-25 | 2003-02-28 | Bioadhesive Progressive Hydration Tablets |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU55826/99A Division AU754880B2 (en) | 1998-08-25 | 1999-08-24 | Extended release buccal bioadhesive tablet |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005203703A Division AU2005203703B2 (en) | 1998-08-25 | 2005-08-12 | Bioadhesive progressive hydration tablets |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003200753A1 AU2003200753A1 (en) | 2003-05-01 |
| AU2003200753B2 true AU2003200753B2 (en) | 2005-05-12 |
Family
ID=39273464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003200753A Ceased AU2003200753B2 (en) | 1998-08-25 | 2003-02-28 | Bioadhesive Progressive Hydration Tablets |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2003200753B2 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4226848A (en) * | 1979-03-05 | 1980-10-07 | Teijin Limited | Method and preparation for administration to the mucosa of the oral or nasal cavity |
| EP0159604A2 (en) * | 1984-04-09 | 1985-10-30 | Toyo Boseki Kabushiki Kaisha | Sustained-release preparation applicable to mucous membrane in oral cavity |
| EP0654261A1 (en) * | 1993-11-24 | 1995-05-24 | Vetoquinol S.A. | Solid mucoadhesive composition, for therapeutic or hygienic use, for administration by application on the nasal or buccal mucose |
-
2003
- 2003-02-28 AU AU2003200753A patent/AU2003200753B2/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4226848A (en) * | 1979-03-05 | 1980-10-07 | Teijin Limited | Method and preparation for administration to the mucosa of the oral or nasal cavity |
| EP0159604A2 (en) * | 1984-04-09 | 1985-10-30 | Toyo Boseki Kabushiki Kaisha | Sustained-release preparation applicable to mucous membrane in oral cavity |
| EP0654261A1 (en) * | 1993-11-24 | 1995-05-24 | Vetoquinol S.A. | Solid mucoadhesive composition, for therapeutic or hygienic use, for administration by application on the nasal or buccal mucose |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6624200B2 (en) | Bioadhesive progressive hydration tablets | |
| EP1105104B1 (en) | Extended release buccal bioadhesive tablet | |
| US7153845B2 (en) | Bioadhesive progressive hydration tablets | |
| US8765177B2 (en) | Bioadhesive progressive hydration tablets | |
| TWI234459B (en) | Eplerenone compositions | |
| US8377977B2 (en) | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof | |
| AU628754B2 (en) | Therapeutic agents | |
| US20240050367A1 (en) | Mucoadhesive Gel Composition | |
| US20050106238A1 (en) | Orodispersible pharmaceutical composition comprising ivabradine | |
| AU2005203703B2 (en) | Bioadhesive progressive hydration tablets | |
| AU2003200753B2 (en) | Bioadhesive Progressive Hydration Tablets | |
| TWI319987B (en) | Bioadhesive progressive hydration tablets | |
| HK1034895B (en) | Extended release buccal bioadhesive tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |